Abilify News
Most Popular Abilify Story
Bristol-Myers' Q4 shows growth in newer products
Bristol-Myers Squibb's ($BMY) earnings didn't reach the Wall Street goalposts, partly because of higher costs, some of them attributed to U.S. healthcare reforms. Sales of its flagship drug, Plavix, Read more...
Latest Headlines
- January 26, 2012
- December 19, 2011
- November 16, 2011
- July 28, 2011
- September 15, 2010
- November 20, 2009
- October 16, 2009
- April 6, 2009
- June 30, 2008
- November 6, 2007
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
